These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1902404)

  • 21. [Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
    Mukawa H; Sone T; Tsuboi H; Kondo J; Kosokabe T; Uesugi M; Imai H
    J Cardiol; 2001 Apr; 37(4):181-9. PubMed ID: 11337927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
    Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
    Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
    Rogers WJ; Babb JD; Baim DS; Chesebro JH; Gore JM; Roberts R; Williams DO; Frederick M; Passamani ER; Braunwald E
    J Am Coll Cardiol; 1991 Apr; 17(5):1007-16. PubMed ID: 1901071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
    Haq A; Morgan CD; Wilson RF; Daly PA; Baigrie RS; White CW; Roberts R; Gent M; Armstrong PW
    Am J Cardiol; 1993 Aug; 72(5):379-83. PubMed ID: 8352178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
    Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant tissue-plasminogen activator (rt-PA) in acute myocardial infarction in the Chinese in Hong Kong.
    Woo KS; Tse KK; Mak YK; Chung HK; Tse CY
    Chin Med J (Engl); 1992 May; 105(5):374-8. PubMed ID: 1499366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
    Morgan CD; Roberts RS; Haq A; Baigrie RS; Daly PA; Gent M; Armstrong PW
    J Am Coll Cardiol; 1991 Jun; 17(7):1451-7. PubMed ID: 1903404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
    Lancet; 1988 Jan; 1(8579):203-8. PubMed ID: 2893038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study.
    van der Meer J; Brutel de la Rivière A; van Gilst WH; Hillege HL; Pfisterer M; Kootstra GJ; Dunselman PH; Mulder BJ; Lie KI
    J Am Coll Cardiol; 1994 Nov; 24(5):1181-8. PubMed ID: 7930237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
    J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
    Cherng WJ; Chiang CW; Kuo CT; Lee CP; Lee YS
    Am Heart J; 1992 Apr; 123(4 Pt 1):841-6. PubMed ID: 1549990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
    J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.